Literature DB >> 24982070

High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea.

Susanne Jacobsson1, Daniel Golparian1, Richard A Alm2, Michael Huband2, John Mueller2, Jorgen Skov Jensen3, Makoto Ohnishi4, Magnus Unemo5.   

Abstract

We evaluated the activity of the novel spiropyrimidinetrione AZD0914 (DNA gyrase inhibitor) against clinical gonococcal isolates and international reference strains (n=250), including strains with diverse multidrug resistance and extensive drug resistance. The AZD0914 MICs were substantially lower than those of most other currently or previously recommended antimicrobials. AZD0914 should be further evaluated, including in vitro selection, in vivo emergence and mechanisms of resistance, pharmacokinetics/pharmacodynamics in humans, optimal dosing, and performance, in appropriate randomized and controlled clinical trials.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24982070      PMCID： PMC4135813          DOI： 10.1128/AAC.03090-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  26 in total

1.  Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds.

Authors:  Trudy H Grossman; Douglas J Bartels; Steve Mullin; Christian H Gross; Jonathan D Parsons; Yusheng Liao; Anne-Laure Grillot; Dean Stamos; Eric R Olson; Paul S Charifson; Nagraj Mani
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

2.  Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010.

Authors:  C A Ison; J Hussey; K N Sankar; J Evans; S Alexander
Journal:  Euro Surveill       Date:  2011-04-07

3.  Failure of 500 mg of ceftriaxone to eradicate pharyngeal gonorrhoea, Australia.

Authors:  Marcus Y Chen; Kerrie Stevens; Robin Tideman; Angelo Zaia; Takehiro Tomita; Christopher K Fairley; Monica Lahra; David Whiley; Geoff Hogg
Journal:  J Antimicrob Chemother       Date:  2013-02-06       Impact factor: 5.790

Review 4.  Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea.

Authors:  Magnus Unemo; Robert A Nicholas
Journal:  Future Microbiol       Date:  2012-12       Impact factor: 3.165

5.  Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada.

Authors:  Vanessa G Allen; Leo Mitterni; Christine Seah; Anuradha Rebbapragada; Irene E Martin; Colin Lee; Heather Siebert; Lynn Towns; Roberto G Melano; Donald E Low
Journal:  JAMA       Date:  2013-01-09       Impact factor: 56.272

6.  Phenotypic and genetic characterization of the first two cases of extended-spectrum-cephalosporin-resistant Neisseria gonorrhoeae infection in South Africa and association with cefixime treatment failure.

Authors:  David A Lewis; Charlotte Sriruttan; Etienne E Müller; Daniel Golparian; Lindy Gumede; Donald Fick; Johan de Wet; Venessa Maseko; Jennifer Coetzee; Magnus Unemo
Journal:  J Antimicrob Chemother       Date:  2013-02-14       Impact factor: 5.790

7.  High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure.

Authors:  Magnus Unemo; Daniel Golparian; Robert Nicholas; Makoto Ohnishi; Anne Gallay; Patrice Sednaoui
Journal:  Antimicrob Agents Chemother       Date:  2011-12-12       Impact factor: 5.191

8.  Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010.

Authors:  M Unemo; D Golparian; A Hestner
Journal:  Euro Surveill       Date:  2011-02-10

9.  Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae.

Authors:  Richard A Alm; Sushmita D Lahiri; Amy Kutschke; Linda G Otterson; Robert E McLaughlin; James D Whiteaker; Lisa A Lewis; Xiaohong Su; Michael D Huband; Humphrey Gardner; John P Mueller
Journal:  Antimicrob Agents Chemother       Date:  2014-12-22       Impact factor: 5.191

10.  Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods.

Authors:  John Tapsall; Phillip Read; Christopher Carmody; Christopher Bourne; Sanghamitra Ray; Athena Limnios; Theo Sloots; David Whiley
Journal:  J Med Microbiol       Date:  2009-05       Impact factor: 2.472
View more
  25 in total

Review 1.  Antibiotics in the clinical pipeline at the end of 2015.

Authors:  Mark S Butler; Mark At Blaskovich; Matthew A Cooper
Journal:  J Antibiot (Tokyo)       Date:  2016-06-29       Impact factor: 2.649

2.  Future treatment of gonorrhea--novel emerging drugs are essential and in progress?

Authors:  Magnus Unemo; William M Shafer
Journal:  Expert Opin Emerg Drugs       Date:  2015-07-03       Impact factor: 4.191

3.  Multidrug-Resistant Neisseria gonorrhoeae Isolates from Nanjing, China, Are Sensitive to Killing by a Novel DNA Gyrase Inhibitor, ETX0914 (AZD0914).

Authors:  Xiao-Hong Su; Bao-Xi Wang; Wen-Jing Le; Yu-Rong Liu; Chuan Wan; Sai Li; Richard A Alm; John P Mueller; Peter A Rice
Journal:  Antimicrob Agents Chemother       Date:  2015-10-19       Impact factor: 5.191

4.  In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae.

Authors:  Stephan A Kohlhoff; Michael D Huband; Margaret R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  2014-10-06       Impact factor: 5.191

5.  In vitro antibacterial activity of AZD0914 against human Mycoplasmas and Ureaplasmas.

Authors:  Ken B Waites; Donna M Crabb; Lynn B Duffy; Michael D Huband
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

6.  Endless Resistance. Endless Antibiotics?

Authors:  Jed F Fisher; Shahriar Mobashery
Journal:  Medchemcomm       Date:  2015-11-03       Impact factor: 3.597

Review 7.  Topoisomerases as anticancer targets.

Authors:  Justine L Delgado; Chao-Ming Hsieh; Nei-Li Chan; Hiroshi Hiasa
Journal:  Biochem J       Date:  2018-01-23       Impact factor: 3.857

8.  Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914.

Authors:  Gunther Kern; Tiffany Palmer; David E Ehmann; Adam B Shapiro; Beth Andrews; Gregory S Basarab; Peter Doig; Jun Fan; Ning Gao; Scott D Mills; John Mueller; Shubha Sriram; Jason Thresher; Grant K Walkup
Journal:  J Biol Chem       Date:  2015-07-06       Impact factor: 5.157

9.  High in vitro susceptibility to the first-in-class spiropyrimidinetrione zoliflodacin among consecutive clinical Neisseria gonorrhoeae isolates from Thailand (2018) and South Africa (2015-2017).

Authors:  Susanne Jacobsson; Ranmini Kularatne; Rossaphorn Kittiyaowamarn; Venessa Maseko; Porntip Paopang; Pongsathorn Sangprasert; Pachara Sirivongrangson; Laura Piddock; Teodora Wi; Emilie Alirol; Magnus Unemo
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

10.  Selective Inhibition of Neisseria gonorrhoeae by a Dithiazoline in Mixed Infections with Lactobacillus gasseri.

Authors:  Jonathan D Lenz; Kristina A Shirk; Adrienne Jolicoeur; Joseph P Dillard
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.